Atopic Dermatitis: An Evidence-Based Treatment Update
Background Atopic dermatitis (AD) is a common inflammatory disorder of skin with significant comorbidities. AD care often requires a combination of treatment approaches, including emollients, topical steroids, systemic immunosuppressants and/or phototherapy. Purpose Our purpose was to review recent randomized controlled trials (RCT) and systematic reviews of AD treatments. Methods A MEDLINE search was performed focusing on RCTs of AD treatments, with a sample size ≥15, and systematic reviews published from 2011 to 2013, limited to the English language. A total of 53 manuscripts met the inclusion/exclusion criteria, including 44 RCTs and nine systematic reviews. Results Investigator-initiated RCTs support the use of the systemic agents cyclosporine, methotrexate, azathioprine and mycophenolate mofetil. In one RCT, petrolatum was found to be as effective as creams containing ceramides or glycyrrhetinic acid. Additional therapeutic approaches supported by RCTs include balneotherapy, oral and/or topical probiotics, nutritional interventions, vitamin D with or without vitamin E supplementation, as well as several new topical and complementary medicines. Conclusions Advances have been made with respect to AD treatment in the past few years through the use of well designed RCTs and comparative efficacy studies. However, more well designed RCTs and investigator-initiated studies are needed in order to improve the care of AD patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
American journal of clinical dermatology - 15(2014), 3 vom: 25. Jan., Seite 149-164 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Silverberg, Jonathan I. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Atopic Dermatitis |
|---|
| doi: |
10.1007/s40257-014-0062-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR032963386 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR032963386 | ||
| 003 | DE-627 | ||
| 005 | 20230519150806.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40257-014-0062-z |2 doi | |
| 035 | |a (DE-627)SPR032963386 | ||
| 035 | |a (SPR)s40257-014-0062-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Silverberg, Jonathan I. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Atopic Dermatitis: An Evidence-Based Treatment Update |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background Atopic dermatitis (AD) is a common inflammatory disorder of skin with significant comorbidities. AD care often requires a combination of treatment approaches, including emollients, topical steroids, systemic immunosuppressants and/or phototherapy. Purpose Our purpose was to review recent randomized controlled trials (RCT) and systematic reviews of AD treatments. Methods A MEDLINE search was performed focusing on RCTs of AD treatments, with a sample size ≥15, and systematic reviews published from 2011 to 2013, limited to the English language. A total of 53 manuscripts met the inclusion/exclusion criteria, including 44 RCTs and nine systematic reviews. Results Investigator-initiated RCTs support the use of the systemic agents cyclosporine, methotrexate, azathioprine and mycophenolate mofetil. In one RCT, petrolatum was found to be as effective as creams containing ceramides or glycyrrhetinic acid. Additional therapeutic approaches supported by RCTs include balneotherapy, oral and/or topical probiotics, nutritional interventions, vitamin D with or without vitamin E supplementation, as well as several new topical and complementary medicines. Conclusions Advances have been made with respect to AD treatment in the past few years through the use of well designed RCTs and comparative efficacy studies. However, more well designed RCTs and investigator-initiated studies are needed in order to improve the care of AD patients. | ||
| 650 | 4 | |a Atopic Dermatitis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Mycophenolate Mofetil |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Topical Corticosteroid |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pimecrolimus |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Mometasone Furoate |7 (dpeaa)DE-He213 | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of clinical dermatology |d Berlin [u.a.] : Springer, 2000 |g 15(2014), 3 vom: 25. Jan., Seite 149-164 |w (DE-627)SPR032954131 |w (DE-600)2043675-0 |x 1179-1888 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2014 |g number:3 |g day:25 |g month:01 |g pages:149-164 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40257-014-0062-z |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2014 |e 3 |b 25 |c 01 |h 149-164 | ||